Relistor Expansion Plans In Question Following “Complete Response” Letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA requested more clinical data on Salix/Progenics’ sNDA for approval of the subcutaneous formulation of methylnaltrexone in chronic, non-cancer pain patients with opioid-induced constipation. The regulatory setback could have implications for the companies’ planned September filing of an oral formulation in the same patient population.
You may also be interested in...
Progenics Finds New Partner For Relistor In Salix
A casualty of the Pfizer/Wyeth merger, Relistor rights bring Progenics $60 million upfront plus up to $290 million in milestones plus royalties.
Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too
Compound helps bowel function in dying patients on opioids.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.